Improving the reporting of allergic adverse events during immunotherapy for food allergy - 03/11/22
Doi : 10.1016/j.jaci.2022.07.012
Paul J. Turner, FRCPCH, PhD a 
, Nandinee Patel, MRCPCH a, Mika J. Mäkelä, MD, PhD b, Kaarina Kukkonen, MD c, Antoine Deschildre, MD d, Katharina Blumchen, MD e, Pablo Rodríguez del Río, MD, PhD f, Montserrat Fernández-Rivas, MD, PhD g, Montserrat Alvaro-Lozano, MD, PhD h, Kirsten Beyer, MD i
, Nandinee Patel, MRCPCH a, Mika J. Mäkelä, MD, PhD b, Kaarina Kukkonen, MD c, Antoine Deschildre, MD d, Katharina Blumchen, MD e, Pablo Rodríguez del Río, MD, PhD f, Montserrat Fernández-Rivas, MD, PhD g, Montserrat Alvaro-Lozano, MD, PhD h, Kirsten Beyer, MD i a National Heart & Lung Institute, Imperial College London, London, United Kingdom
b Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki,Helsinki, Finland
c Children’s Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
d CHU Lille, Univ. Lille, Pediatric Pulmonology and Allergy Department, Hôpital Jeanne de Flandre, Lille, France
e Department of Paediatric and Adolescent Medicine, Pneumology, Allergology and Cystic fibrosis, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
f Hospital Universitario Niño Jesús, ARADyAL, Madrid, Spain
g Allergy Department, Hospital Clínico San Carlos, Facultad de Medicina, Universidad Complutense (UCM), IdISSC, ARADyAL, Madrid
h Pediatric Allergology and Clinical Immunology Hospital Sant Joan de Déu; Institut de Recerca Sant Joan de Déu; Universitat de Barcelona, Spain
i Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universtãtsmedizin Berlin, Berlin, Germany
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: P. J. Turner reports grants from UKMedical Research Council, NIHR/Imperial BRC, and JM Charitable Foundation; and personal fees from UKFood Standards Agency, Aimmune Therapeutics, Allergenis, and Aquestive Therapeutics, outside the submitted work. M. J. Mäkelä reports fees from GlaxoSmithKline (GSK) and Orion Pharma, outside the submitted work. K. Blumchen reports consulting for Aimmune Therapeutics, DBV Technologies, Bencard Allergie, and Novartis; speakers bureau for Aimmune Therapeutics, DBV Technologies, HAL Allergy, Nutricia, Thermo Fisher Scientific, ALK, Allergopharma, Nestle, and Novartis; and research grants from Aimmune Therapeutics, DBV Technologies, Novartis, and Hipp, outside the submitted work A. Deschildre reports personal fees from ALK, Stallergènes-Greer, GSK, Novartis, Sanofi, Regeneron, Bohringer Ingelheim, Aimmune Therapeutics, DBV Technologies, Nestlé Health Science, and Nutricia, outside the submitted work. P. Rodríguez del Río was a site investigator in the PALISADE and the ARTEMIS studies, and reports grants from the Spanish Society of Allergy and Clinical Immunology (SEAIC) and lecturing fees from Aimmune Therapeutics, FAES, GSK, Novartis, ALK, Sanofi, Stallergenes, and Miravo. M. Fernández-Rivas reports research grants to her institution from EU FP7 (iFAAM project), the Spanish government (MINECO, ISCIII), and Aimmune Therapeutics and Diater; consultancy fees from Aimmune Therapeutics, Novartis, and SPRIM; fees for participation in DSMB from DBV; and lecture fees from Aimmune Therapeutics, ALK, Allergy Therapeutics, Diater, GSK, HAL Allergy, and ThermoFisher Scientific, outside the submitted work. K. Beyer reports advisory board/consulting fees from Aimmune Therapeutics, ALK, Bausch & Lomb, Bencard, Danone, DBV, Hycor, Infectopharm, Mabylon, Meda Pharma, Mylan, and Nestle; speakers bureau for Aimmune Therapeutics, Allergopharma, Bencard, Danone, Di-Text, Hammer und Rall Media, Infectopharm, Meda Pharma, Med Update, Nestle, and Nutricia; and research grants from Aimmune, ALK, Danone, DBV, Good Mills, Hipp, Hycor, Infectopharm, Nutricia, ThermoFisher, and VDI, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2022
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 150 - N° 5
P. 1242-1244 - novembre 2022 Retour au numéro
Article précédent
- STAT3-confusion-of-function: Beyond the loss and gain dualism
- Lorenzo Lodi, Laura Eva Faletti, Maria Elena Maccari, Filippo Consonni, Miriam Groß, Ilaria Pagnini, Silvia Ricci, Maximilian Heeg, Gabriele Simonini, Chiara Azzari, Stephan Ehl
- Reply
- R. Sharon Chinthrajah, Alkis Togias, Robert A. Wood, OUtMATCH Study Team
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?